FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:585-592 August 5, 2004 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers are used commonly in clinical practice to treat hypertension and decrease cardiovascular events in high-risk patients. A side effect of such therapy is the development of hyperkalemia. Hyperkalemia has been attributed to the use of ACE inhibitors in 10 to 38 percent of hospitalized patients with this complication.^1,2,3,4 Hyperkalemia develops in approximately 10 percent of outpatients within a year after these drugs are prescribed.⁵ Patients at greatest risk for hyperkalemia include those with diabetes and those with impaired renal function in whom a defect in the excretion of renal potassium may already exist.

Hyperkalemia . . . [Full Text of this Article]

Normal Handling of Potassium in the Kidney

Induction of Hyperkalemia

Decreased Distal Delivery of Sodium

Decreased Aldosterone Activity

Abnormal Functioning of the Cortical Collecting Tubule

Minimizing the Risk of Hyperkalemia

Source Information

From the Department of Medicine, Division of Nephrology, University of Texas Southwestern Medical School, Dallas.

Address reprint requests to Dr. Palmer at the Department of Medicine, University of Texas Southwestern Medical School, 5323 Harry Hines Blvd., Dallas, TX 75390-8856, or at biff.palmer@utsouthwestern.edu.

Related Letters:

Hyperkalemia and Inhibitors of the Renin–Angiotensin–Aldosterone System
Segal A., Palmer B. F.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:2450-2451, Dec 2, 2004. Correspondence

This article has been cited by other articles:

• HIRSCH, S. (2008). An update on proteinuric chronic kidney disease: The dual-goal approach. Cleveland Clinic Journal of Medicine 75: 705-713 [Abstract] [Full Text]  
• Henz, S., Maeder, M. T., Huber, S., Schmid, M., Loher, M., Fehr, T. (2008). Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions. Nephrol Dial Transplant 0: gfn380v1-gfn380 [Abstract] [Full Text]  
• Desai, A. S., Swedberg, K., McMurray, J. J.V., Granger, C. B., Yusuf, S., Young, J. B., Dunlap, M. E., Solomon, S. D., Hainer, J. W., Olofsson, B., Michelson, E. L., Pfeffer, M. A., on behalf of the CHARM Program Investigators, (2007). Incidence and Predictors of Hyperkalemia in Patients With Heart Failure: An Analysis of the CHARM Program. J Am Coll Cardiol 50: 1959-1966 [Abstract] [Full Text]  
• Coleman, C. I, Makanji, S., Kluger, J., White, C M. (2007). Effect of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on the Frequency of Post-Cardiothoracic Surgery Atrial Fibrillation. The Annals of Pharmacotherapy 41: 433-437 [Abstract] [Full Text]  
• Raebel, M. A, McClure, D. L, Chan, K A., Simon, S. R, Feldstein, A. C, Lafata, J. E., Andrade, S. E, Gunter, M. J, Nelson, W. W, Roblin, D., Platt, R. (2007). Laboratory Evaluation of Potassium and Creatinine Among Ambulatory Patients Prescribed Spironolactone: Are We Monitoring for Hyperkalemia?. The Annals of Pharmacotherapy 41: 193-200 [Abstract] [Full Text]  
• Martin, U., Coleman, J. J (2006). Monitoring renal function in hypertension.. BMJ 333: 896-899 [Full Text]  
• Formica, R. N. Jr, Friedman, A. L., Lorber, M. I., Smith, J. D., Eisen, T., Bia, M. J. (2006). A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 21: 1389-1394 [Abstract] [Full Text]  
• Kraft, M. D., Btaiche, I. F., Sacks, G. S., Kudsk, K. A. (2006). Preferred treatment of hyperkalemia. Am J Health Syst Pharm 63: 514-516 [Full Text]  
• Marcy, T. R., Ripley, T. L. (2006). Aldosterone antagonists in the treatment of heart failure. Am J Health Syst Pharm 63: 49-58 [Abstract] [Full Text]  
• Warnock, D. G., Rossier, B. C. (2005). Renal Sodium Handling: The Role of the Epithelial Sodium Channel. J. Am. Soc. Nephrol. 16: 3151-3153 [Full Text]  
• Gil, P., Justo, S., Caramelo, C. (2005). Cardio-renal failure: an emerging clinical entity. Nephrol Dial Transplant 20: 1780-1783 [Full Text]  
• Warnock, D. G., Bell, P. D. (2005). Improvement of Blood Pressure With Inhibition of the Epithelial Sodium Channel in Blacks With Hypertension. Hypertension 46: 469-470 [Full Text]  
• Buck, M. L (2005). Clinical Experience with Spironolactone in Pediatrics. The Annals of Pharmacotherapy 39: 823-828 [Abstract] [Full Text]  
• Humphreys, B. D., Soiffer, R. J., Magee, C. C. (2005). Renal Failure Associated with Cancer and Its Treatment: An Update. J. Am. Soc. Nephrol. 16: 151-161 [Full Text]  
• Goldfarb, D. S., Newsome, B. B., Warnock, D. G., Witham, M. D., Gillespie, N. D., Struthers, A. D., Cavallari, L., Vaitkus, P., Groo, V., Juurlink, D. N., Mamdani, M. M., Redelmeier, D. A. (2004). Hyperkalemia after the Publication of RALES. NEJM 351: 2448-2450 [Full Text]  
• Segal, A., Palmer, B. F. (2004). Hyperkalemia and Inhibitors of the Renin-Angiotensin-Aldosterone System. NEJM 351: 2450-2451 [Full Text]